Patients exhibiting the high interferon gene signature—a key biomarker for lupus—typically show a stronger response to therapies like envudeucitinib while maintaining lower placebo rates. Because these individuals were scarce in the study population, the aggregate results failed to reach statistical significance. Despite this setback, Alumis reported that the specific subgroup of high-interferon patients demonstrated robust clinical responses to the medication.

Looking ahead, the company plans to consult with regulators regarding a potential Phase 3 trial. The drug maintained a favorable safety profile with no new concerns reported during the study. Alumis confirmed that this development does not impact its other pipeline activities; the company remains on schedule to submit a new drug application for envudeucitinib in moderate-to-severe plaque psoriasis during the fourth quarter of this year.